To the Editor: Chevron and coworkers (Oct. 27 issue)1 reportedthe absence of immunostaining for utrophin on the surface ofmuscle fibers in an unidentified muscle from a boy with a formof muscular dystrophy who died at the age of 15 years. An absenceof immunostaining for dystrophin was also observed. These datawere interpreted as being indicative of the absence of the expressionof both dystrophin and utrophin, possibly because of the absenceof a common intramembranous (plasmalemmal) protein that bindsboth dystrophin and utrophin. The authors correctly point outthat in normal skeletal muscle, utrophin is . . . [Full Text of this Article]
Karthikeyan, K
(2005). Treatment of scabies: newer perspectives. Postgrad. Med. J.
81: 7-11
[Abstract][Full Text]
Chouela, E. N., Abeldano, A. M., Pellerano, G., La Forgia, M., Papale, R. M., Garsd, A., del Carmen Balian, M., Battista, V., Poggio, N.
(1999). Equivalent Therapeutic Efficacy and Safety of Ivermectin and Lindane in the Treatment of Human Scabies. Arch Dermatol
135: 651-655
[Abstract][Full Text]
del Giudice, P., Marty, P.
(1999). Ivermectin: A New Therapeutic Weapon in Dermatology?. Arch Dermatol
135: 705-706
[Full Text]
Jaramillo-Ayerbe, F., Berrio-Munoz, J.
(1998). Ivermectin for Crusted Norwegian Scabies Induced by Use of Topical Steroids. Arch Dermatol
134: 143-145
[Full Text]
Liu, L. X., Weller, P. F.
(1996). Antiparasitic Drugs. NEJM
334: 1178-1184
[Full Text]
Meinking, T. L., Taplin, D., Herminda, J. L., Pardo, R., Kerdel, F. A.
(1995). The Treatment of Scabies with Ivermectin. NEJM
333: 26-30
[Abstract][Full Text]